ArticleFrontiers in oncology2026
Association between splenic volume changes and prognosis in advanced gastric cancer patients receiving chemotherapy combined with immunotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: The prognostic value of splenic volume (SV) in patients with advanced gastric cancer receiving chemotherapy combined with immunotherapy remains unclear. This study aimed to evaluate the association between CT-assessed changes in SV and clinical outcomes, exploring its potential as a prognostic biomarker. Methods: This retrospective cohort study included 138 advanced gastric cancer patients receiving chemotherapy combined with immunotherapy. Patients were stratified into an increased group (ΔSV > 14%, n = 87) and a non-increased group (ΔSV ≤ 14%, n = 51) based on the optimal cutoff value of 14% for the annualized change in splenic volume (ΔSV). Kaplan-Meier survival analysis, Cox proportional hazards models, and restricted cubic spline analyses were used to assess prognostic associations. A nomogram incorporating ΔSV was constructed for survival prediction. Results: The increased group showed significantly shorter median progression-free survival (PFS) (14.8 vs. 26.6 months, Conclusions: Increased SV is associated with poorer clinical outcomes in advanced gastric cancer patients receiving chemotherapy combined with immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.